Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported net income for the third quarter of 2024, compared to a loss last year
Earnings Summary: Moderna swings to profit in Q3 on modest revenue growth
Categories
Biotechnology
Key metrics from Bristol Myers Squibb’s (BMY) Q3 2024 earnings results
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2024 earnings results today. Total revenues increased 8% year-over-year to $11.9 billion. Revenues
Key highlights from Biogen’s (BIIB) Q3 2024 earnings results
Biogen Inc. (NASDAQ: BIIB) reported its third quarter 2024 earnings results today. Total revenue decreased 3% year-over-year to $2.46 billion. Revenues were
Abbott Laboratories (ABT) Q3 2024 Earnings: Key financials and quarterly highlights
Abbott Laboratories (NYSE: ABT) reported third quarter 2024 earnings results today. Total reported sales increased 4.9% year-over-year to $10.6 billion. Organic sales
TRxADE Health changes its name to Scienture Holdings
Trxade Health, Inc. (NASDAQ: MEDS), a leading health services IT company, and its wholly owned subsidiary Scienture, LLC revealed that Trxade has
IPO News: Everything you need to know about BioAge Labs’ IPO
BioAge Labs, Inc. is the latest among the healthcare companies pursuing stock-market listing this year. In a registration statement filed with the
Ocean Biomedical (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a preclinical biotech company focused on moving new therapeutic candidates efficiently from the laboratory to the
Trxade Health (MEDS) Q2 2024 Research Summary
Trxade Health, Inc. (NASDAQ: MEDS) is a drug procurement and delivery platform with a mission to revolutionize the healthcare industry by offering
MEDS Earnings: A snapshot of Trxade’s Q2 2024 results
Health services IT company Trxade Health, Inc. (NASDAQ: MEDS) announced financial results for the second quarter of 2024, reporting a narrower net
Earnings Summary: Gilead Sciences reports higher Q2 revenue and profit
Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, has reported an increase in revenues and adjusted earnings for the second
LLY Earnings: Highlights of Eli Lilly’s Q2 2024 financial report
Eli Lilly and Company (NYSE: LLY) on Thursday reported a double-digit increase in revenues and profit for the second quarter of 2024.
Earnings Summary: Moderna reports Q2 2024 financial results
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported a sharp decline in revenues for the second quarter of 2024. Second-quarter revenues decreased
Merck (MRK) swings to profit in Q2 on higher revenues; earnings beat
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported net profit for the second quarter of 2024, on an adjusted basis, compared
BMY Earnings: Bristol-Myers Squibb reports higher Q2 revenue and profit
Biotechnology company Bristol Myers Squibb (NYSE: BMY) Friday reported higher revenues and net profit for the second quarter of 2024. Net income
Everything you need to know about OS Therapies’ upcoming IPO
There has been a strong uptick in IPO activity this year compared to 2023 when the market witnessed a slowdown. In the
Alumis looks to raise $300 million in IPO. Here’s what you need to know
Technology and healthcare companies are continuing to dominate the IPO market, which is witnessing a significant increase in activity compared to 2023.
Ocean Biomedical (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a new-generation biotechnology firm that works to accelerate the development of new therapies by partnering with
Cigna Group (CI) reports double-digit revenue growth for Q1; guides FY24
The Cigna Group (NYSE: CI), a healthcare company focused on medical insurance and related services, Thursday reported a sharp increase in revenues for
Infographic: A snapshot of Moderna’s (MRNA) Q1 2024 earnings results
Moderna, Inc. (NASDAQ: MRNA) reported a net loss for the first quarter of 2024 when the biotechnology company's revenues declined sharply. Q1
MRK Earnings: Merck Q1 2024 profit jumps on 9% revenue growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided
BIIB Earnings: Biogen Q1 2024 adj. earnings rise despite lower revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Wednesday reported an increase in adjusted profit for the first quarter of 2024, despite a decline